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Chronic administration of aripiprazole activates GSK3β-dependent
signalling pathways, and up-regulates GABAA receptor expression and
CREB1 activity in rats
Abstract

Aripiprazole is a D2-like receptor (D2R) partial agonist with a favourable clinical profile. Previous
investigations indicated that acute and short-term administration of aripiprazole had effects on PKA activity,
GSK3β-dependent pathways, GABAA receptors, NMDA receptor and CREB1 in the brain. Since
antipsychotics are used chronically in clinics, the present study investigated the long-term effects of chronic
oral aripiprazole treatment on these cellular signalling pathways, in comparison with haloperidol (a D2R
antagonist) and bifeprunox (a potent D2R partial agonist). We found that the Akt-GSK3β pathway was
activated by aripiprazole and bifeprunox in the prefrontal cortex; NMDA NR2A levels were reduced by
aripiprazole and haloperidol. In the nucleus accumbens, all three drugs increased Akt-GSK3β signalling; in
addition, both aripiprazole and haloperidol, but not bifeprunox, increased the expression of Dvl-3, β-catenin
and GABAA receptors, NMDA receptor subunits, as well as CREB1 phosphorylation levels. The results
suggest that chronic oral administration of aripiprazole affects schizophrenia-related cellular signalling
pathways and markers (including Akt-GSK3β signalling, Dvl-GSK3β-β-catenin signalling, GABAA receptor,
NMDA receptor and CREB1) in a brain-region-dependent manner; the selective effects of aripiprazole on
these signalling pathways might be associated with its unique clinical effects.
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Chronic administration of
aripiprazole activates GSK3βdependent signalling pathways,
and up-regulates GABAA receptor
expression and CREB1 activity
in rats
Bo Pan1,2, Xu-Feng Huang2 & Chao Deng1,2
Aripiprazole is a D2-like receptor (D2R) partial agonist with a favourable clinical profile. Previous
investigations indicated that acute and short-term administration of aripiprazole had effects on PKA
activity, GSK3β-dependent pathways, GABAA receptors, NMDA receptor and CREB1 in the brain.
Since antipsychotics are used chronically in clinics, the present study investigated the long-term
effects of chronic oral aripiprazole treatment on these cellular signalling pathways, in comparison with
haloperidol (a D2R antagonist) and bifeprunox (a potent D2R partial agonist). We found that the AktGSK3β pathway was activated by aripiprazole and bifeprunox in the prefrontal cortex; NMDA NR2A
levels were reduced by aripiprazole and haloperidol. In the nucleus accumbens, all three drugs increased
Akt-GSK3β signalling; in addition, both aripiprazole and haloperidol, but not bifeprunox, increased
the expression of Dvl-3, β-catenin and GABAA receptors, NMDA receptor subunits, as well as CREB1
phosphorylation levels. The results suggest that chronic oral administration of aripiprazole affects
schizophrenia-related cellular signalling pathways and markers (including Akt-GSK3β signalling,
Dvl-GSK3β-β-catenin signalling, GABAA receptor, NMDA receptor and CREB1) in a brain-regiondependent manner; the selective effects of aripiprazole on these signalling pathways might be
associated with its unique clinical effects.
Aripiprazole is a unique antipsychotic drug with a pharmacological profile different from other available antipsychotics, and this difference has been attributed to its partial agonism for the dopamine D2 receptor (D2R). A
large body of evidence has shown that most antipsychotic drugs (including aripiprazole and haloperidol) have
a potent affinity at the D2Rs1, regulating the D2R downstream protein kinase B (Akt)-glycogen synthase kinase
3 beta (GSK3β) and protein kinase A (PKA) signalling pathways2. In addition, these two signalling pathways
are also linked to several other pathways or substrates, such as the dishevelled(Dvl)-GSK3β-β-catenin pathway,
γ-aminobutyric acid (GABA)A receptor and cAMP-responsive element-binding protein 1 (CREB1)3–5.
GSK3β-dependent signalling pathways are involved in the pathophysiology of schizophrenia and the actions
of antipsychotics4. First, GSK3βis a major downstream regulator of D2-like receptors that is targeted by most
antipsychotics6. It has been reported that chronic haloperidol treatment phosphorylates GSK3β, and inhibits its
activity, which is associated with increased phosphorylation levels of Akt in the frontal cortex7. Second, antipsychotic administration can also influence the Dvl-GSK3β-β-catenin signalling pathway. Several studies have
reported that various antipsychotics (including clozapine, haloperidol, risperidone, olanzapine and aripiprazole)
were able to increase phosphorylation of GSK3βand expression of Dvl and β-catenin in the frontal cortex and
striatum8–12.
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The G protein-dependent PKA pathway is another downstream signalling pathway of D2-like receptors. PKA
signalling has been shown to be related to the pathophysiology of schizophrenia by a post-mortem study13. An
in vivo study has indicated that acute administration of haloperidol and olanzapine increased the expression
of PKA catalytic subunits in the rat caudate putamen (CPu)14; PKA signalling has also been elevated by acute
administration of haloperidol in the striatum15; and furthermore, the activity of the PKA pathway and expression
of PKA regulatory subunits in the striatum were elevated after a 3-week administration of haloperidol in various
brain regions, but decreased by clozapine administration16. A recent study has shown that 1-week administration
of aripiprazole increased PKA phosphorylation in the nucleus accumbens (NAc), but reduced it in the CPu, while
haloperidol decreased it in both the NAc and CPu17.
The GABAA receptor has been reported to be involved in the pathophysiology of schizophrenia18. Increased
binding density of GABAA receptors have been found in the prefrontal cortex (PFC)19,20, cingulate cortex21,
superior temporal gyrus22 and hippocampus23 of schizophrenic subjects. Antipsychotic administration has been
shown to have various effects on GABAA receptors. It has been reported that 1-week treatment with both haloperidol and olanzapine increased the binding density of [3H]-Muscimol labelled GABAA receptors24 in the PFC.
Zink and colleagues25 have found that haloperidol administration for 6 months increased the binding density of
GABAA receptors in the CPu and core of the NAc, but reduced it in the PFC, anterior cingulate and infralimbic
cortex; and 6-month clozapine administration reduced the bindings of GABAA receptors in the anterior cingulate
and infralimbic cortex. Recent data suggested that expression of GABAA receptors in the rat NAc was elevated by
1-week aripiprazole administration, probably by activation of the PKA pathway17.
CREB1 is also a downstream substrate of the PKA pathway26. Novel variants in the CREB1 gene have been
identified in schizophrenic subjects, and a relationship between CREB1 and the positive symptoms of schizophrenia has been proposed27. Previous in vivo and in vitro studies have shown that haloperidol increased phosphorylation levels of CREB128–30. Additionally, amisulpride, clozapine and olanzapine also elevated phosphorylation
levels of CREB1 in vitro31–33. Furthermore, a 3-week injection of aripiprazole changed the phosphorylation levels
of CREB1 in the PFC and striatum of rats, probably through NMDA receptors34. A recent short-term study has
reported that aripiprazole increased the gene and protein expression of CREB1, probably through the PKA pathway, in the NAc of rats17.
N-methyl-D-aspartate receptors (NMDARs) have been shown to be associated with schizophrenia and can
be modulated by antipsychotics5. Blockade of NMDARs exacerbates symptoms in schizophrenia individuals35
or induces abnormal behaviours that resemble the symptoms and cognitive deficits of schizophrenia in healthy
subjects36,37. Previous studies showed that antipsychotic drug administration had various effects on NMDARs,
depending on the classes of antipsychotics, treatment methods (e.g. dosages, modes of drug delivery and time
frames) and brain regions38–41. Therefore, the NMDAR subunits were also examined in the present long-term
study.
Recent in vivo studies showed that acute and short-term administration of aripiprazole – a potent D2R partial agonist – displayed different effects that cannot be achieved by haloperidol (a typical antipsychotic and a
potent D2R antagonist) and bifeprunox (a potent D2R partial agonist), providing preliminary in vivo evidence
that neither D2R partial agonism nor D2R antagonism could be solely explain the pharmacological mechanism
and unique clinical effects of aripiprazole17,42. It should also be noted that in clinics, antipsychotics require a long
treatment period to reach maximum therapeutic effect, and thus are often used chronically43. All previous chronic
studies administered antipsychotics by various methods (e.g. mixing in drinking water, daily injection), rather
than the oral administration that mimics the clinical situation. The chronic effects of aripiprazole by such oral
administration are not clear. Therefore, the present study investigated the effects of 10-week oral administration
of aripiprazole by examining PKA signalling, Akt-GSK3βand Dvl-GSK3β-β-catenin pathways, GABAA receptors
and CREB1 activity, in comparison with haloperidol and bifeprunox.

Results

The effect of antipsychotics on Akt and GSK3β activity. PFC. It has been shown that the expression

of total Akt and total GSK3βwas significantly affected by 10-week antipsychotic drug administration in the PFC
(Akt, F3, 20 =  5.201, p =  0.004; GSK3β, F3, 20 =  3.083, p = 0.026); however, the levels of p-Akt and p-GSK3βwere not
significantly affected (p-Akt, F3, 20 =  1.554, p =  0.232; p-GSK3β, F3, 20 =  1.208, p = 0.332). The ratio of p-Akt/Akt
(F3, 20 =  4.523, p = 0.007) and p-GSK3β/GSK3β (F3, 20 =  4.112, p = 0.010) was also significantly affected by antipsychotic drug administration. Post-hoc testing demonstrated that chronic administration of both aripiprazole
and bifeprunox reduced expression of Akt (aripiprazole, −14.2%, p =  0.014; bifeprunox, −13.6%, p =  0.008) in
the PFC (Fig. 1A,D). Additionally, administration of aripiprazole significantly suppressed GSK3βexpression (by
25.0%; p = 0.043) compared with controls (Fig. 2A,D). The levels of p-Akt and p-GSK3βwere not significantly
affected. In addition, aripiprazole and bifeprunox administration significantly increased the ratio of p-Akt/Akt
(aripiprazole, p =  0.021; bifeprunox, p = 0.005) (Fig. 1A). The ratio of p-GSK3β/GSK3βwas also increased by
administration of aripiprazole (p = 0.012) and bifeprunox (p =  0.019) (Fig. 2A).
CPu. Chronic antipsychotic drug administration had no significant effects on the levels of Akt, p-Akt (Fig. 1B,D),
GSK3βand p-GSK3β(Fig. 2B,D) in the CPu compared with controls (all p >  0.05).
NAc. Drug treatment was able to significantly change the levels of p-Akt (F3, 20 =  4.315, p =  0.009), p-GSK3β
(F3, 20 =  9.798, p < 0.001), as well as the ratio of p-Akt/Akt (F3, 20 =  5.268, p = 0.004) and p-GSK3β/ GSK3β (F3, 20 =  7.024,
p = 0.001) in the NAc. Compared with the control group, both bifeprunox and haloperidol administration
significantly elevated the levels of p-Akt in the NAc (bifeprunox, +38.1%, p =  0.010; haloperidol, +40.8%,
p = 0.006); aripiprazole also tended to increase the levels of p-Akt (+25.3%, p = 0.072) (Fig. 1C,D). All three
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Figure 1. Effects of three antipsychotics on Akt activity. The effects of aripiprazole (ARI), bifeprunox (BIF)
and haloperidol (HAL) on Akt activity were measured in the prefrontal cortex (A), caudate putamen (B) and
nucleus accumbens (C). The representative bands of Western blot are shown in (D). Akt was quantified at
60 kDa; p-Akt was quantified at 60 kDa. The data were normalised by taking the average value of the control
group as 100% and expressed as mean ±  S.E.M. (*p ≤  0.05, **p <  0.01 vs the control).

Figure 2. Effects of three antipsychotics on GSK3β activity. The effects of aripiprazole (ARI), bifeprunox
(BIF) and haloperidol (HAL) on GSK3βactivity were measured in the prefrontal cortex (A), caudate putamen
(B) and nucleus accumbens (C). The representative bands of Western blot are shown in (D). GSK3β was
quantified at 46 kDa; p-GSK3βwas quantified at 46 kDa. The data were normalised by taking the average value
of the control group as 100% and expressed as mean ±  S.E.M. (*p ≤  0.05, **p <  0.01 vs the control).
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Figure 3. Effects of three antipsychotics on Dvl-3, β-catenin and GABAA (β-1) receptor expression.
The effects of aripiprazole (ARI), bifeprunox (BIF) and haloperidol (HAL) on the expression of Dvl-3 and
β-catenin were measured in the prefrontal cortex (A), caudate putamen (B) and nucleus accumbens (C). The
representative bands of Western blot are shown in (D). Dvl-3 was quantified at 85 kDa; β-catenin was quantified
at 92 kDa; GABAA (β-1) receptor was quantified at 54 kDa. The data were normalised by taking the average value
of the control group as 100% and expressed as mean ±  S.E.M. (*p ≤  0.05, **p <  0.01 vs the control).

drugs increased the ratio of p-Akt/Akt (aripiprazole, p =  0.044; bifeprunox, p =  0.007; haloperidol, p =  0.002)
(Fig. 1C). Furthermore, administration of all three was able to elevate the levels of p-GSK3β  (aripiprazole,
+69.3%, p <  0.001; bifeprunox, +33.2%, p =  0.026; haloperidol, +38.4%, p = 0.010) (Fig. 2C,D) and significantly
increased the ratio of p-GSK3β/GSK3β (aripiprazole, p =  0.001; bifeprunox, p =  0.048; haloperidol, p =  0.005)
(Fig. 2C).

The effect of antipsychotics on Dvl-3 and β-catenin expression. Chronic antipsychotic administration had significant effects on the expression of Dvl-3 (F3, 20 =  4.629, p =  0.007) and β-catenin (F3, 20 =  15.704,
p < 0.001) in the NAc. Post-hoc tests indicated that the protein levels of Dvl-3 were significantly elevated by
administration of both aripiprazole (+40.8%, p = 0.011) and haloperidol (+33.7%, p = 0.031) in the NAc; they
also significantly increased the expression of β-catenin (aripiprazole, +30.3%, p =  0.008; haloperidol, +49.6%,
p < 0.001) (Fig. 3C,D). Additionally, the ratio of p-GSK3β/GSK3βwas positively correlated with the expression of
β-catenin (r = 0.297, p = 0.039) (Fig. 4A). On the other hand, no significant effect was observed in the other two
brain areas (Fig. 3A,B,D).
The effect of antipsychotics on GABAA receptor expression. GABAA receptors containing β-1 sub-

unit were examined in the present study. The expression of GABAA β-1 receptors in the NAc was significantly
affected by antipsychotic drug administration (F3, 20 =  4.926, p = 0.005). Both aripiprazole and haloperidol administration significantly increased GABAA β-1 receptor expression in the NAc, (aripiprazole, +19.8%, p =  0.008;
haloperidol, +22.7%, p = 0.003) (Fig. 3C,D) but not in the PFC and CPu (Fig. 3A,B,D).

The effects of antipsychotics on NMDAR subunits expression. PFC. The expression of NR2A
was significantly altered by antipsychotic drug administration in the PFC (F3, 20 =  4.976, p = 0.010), but not NR1
(F3, 20 =  1.067, p = 0.137). Post-hoc tests revealed that NR2A levels were reduced by both aripiprazole (−19.9%,
p = 0.020) and haloperidol (−27.9%, p =  0.002) (Fig. 5A,D).
CPu. The expression of NR1 and NR2A was not affected by drug administration in the CPu (NR1, F3, 20 =  0.082,
p =  0.969; NR2A, F3, 20 =  0.909, p =  0.454) (Fig. 5B,D).
NAc. Both NR1 and NR2A expression was significantly changed by antipsychotic drug administration (NR1,
F3, 20 =  4.653, p =  0.013; NR2A, F3, 20 =  6.923, p = 0.002). Post-hoc tests showed that aripiprazole increased the
expression of both NR1 (+36.3%, p = 0.006) and NR2A (+41.9%, p = 0.001); haloperidol also elevated NR1
expression (+27.4%, p = 0.033) in the NAc (Fig. 5C,D).
Scientific Reports | 6:30040 | DOI: 10.1038/srep30040
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Figure 4. Correlations between the ratio of p-GSK3β/GSK3β and the ratio of the expression of β-catenin,
and the ratio of p-CREB1/CREB1 in the NAc. The ratio of p-GSK3β/GSK3βwas positively correlated with the
expression of β-catenin (A), as well as the ratio of p-CREB1/CREB1 (B).

Figure 5. Effects of three antipsychotics on NMRA receptor subunits expression. The effects of aripiprazole
(ARI), bifeprunox (BIF) and haloperidol (HAL) on the expression of NMDA receptor subunits NR1 and
NR2A were measured in the prefrontal cortex (A), caudate putamen (B) and nucleus accumbens (C). The
representative bands of Western blot are shown in (D). NR1 was quantified at 105 kDa; NR2A was quantified at
165 kDa. The data were normalised by taking the average value of the control group as 100% and expressed as
mean ±  S.E.M. (*p ≤  0.05, **p <  0.01 vs the control).

The effect of antipsychotics on CREB1 activity. The levels of CREB1 and p-CREB1 in the PFC
and CPu were not altered by any of the three antipsychotic drug administration (Fig. 6A,B,D). In the NAc,
antipsychotic drug administration had a significant effect on CREB1 (F 3, 20 =  2.502, p =  0.045), p-CREB1
(F3, 20 =  10.698, p < 0.001), as well as the ratio of p-CREB1/CREB1 (F3, 20 =  5.972, p = 0.002). Post-hoc tests showed
that the expression of CREB1 was significantly elevated by administration of aripiprazole (+30.5%; p =  0.020).
Additionally, the levels of p-CREB1 were significantly promoted by aripiprazole (+90.0%, p < 0.001) and haloperidol (+68.8%, p = 0.002) in the NAc (Fig. 6C,D); they also elevated the ratio of p-CREB1/CREB1 (aripiprazole,
p =  0.019; haloperidol, p = 0.004) (Fig. 6C). Furthermore, the ratio of p-GSK3β/GSK3βwas positively correlated
with the ratio of p-CREB1/CREB1 (r =0.572, p = 0.012) in the NAc (Fig. 4B).
The effect of antipsychotics on PKA activity.

The levels of PKA-Cαand p-PKA-C were not changed in
any brain regions after chronic antipsychotic administration in the present study (data not shown).
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Figure 6. Effects of three antipsychotics on CREB1 activity. The effects of aripiprazole (ARI), bifeprunox
(BIF) and haloperidol (HAL) on CREB1 activity were measured in the prefrontal cortex (A), caudate putamen
(B) and nucleus accumbens (C). The representative bands of Western blot are shown in (D). CREB1 was
quantified at 40 kDa; p-CREB1 was quantified at 37 kDa. The data were normalised by taking the average value
of the control group as 100% and expressed as mean ±  S.E.M. (*p ≤  0.05, **p <  0.01 vs the control).

Discussion

The present study investigated the chronic effects of aripiprazole on Akt-GSK3βand Dvl-GSK3β-β-catenin signalling, PKA activity, GABAA (containing β-1) receptor expression, NMDAR subunits expression and CREB1
activity in three brain regions, compared with haloperidol and bifeprunox. This is the first study to examine the
chronic in vivo effects of aripiprazole on these cellular signalling pathways. The results have shown that all three
antipsychotics had different effects on these signalling pathways, depending on the antipsychotic and the brain
region.
Elevated Akt-GSK3βsignalling in the pathophysiology of schizophrenia has been reported in a number of
studies4,7,44–47. Various antipsychotics have shown increasing effects on the Akt-GSK3βsignalling pathway in
previous studies7–9,48,49. Previous acute and 1-week studies have also demonstrated that both aripiprazole and
haloperidol increase the levels of p-GSK3β, but not p-Akt12,42. In the current study, chronic administration of all
three drugs was able to increase the ratio of p-Akt/Akt and p-GSK3β/GSK3βin various brain regions, indicating reduced GSK3βactivity in these brain areas; this is generally consistent with the findings of previous acute
and short-term studies. It is worthy to note that aripiprazole is not only a D2R partial agonist, but also a biased
antagonist at the β-arrestin250. It has been shown that inhibition of D2R mediated β-arrestin2-GSK3β signalling
pathway is a common property that contributes to the therapeutic effects of various antipsychotics, including
aripiprazole50–52, which has been confirmed in this chronic study. It should also be noted that antipsychotics
affect Akt-GSK3βsignalling in a time-dependent manner. Roh et al.53 found that the duration of p-Akt signalling
induced by antipsychotics (about 1 hour) was much shorter than that of p-GSK3β. The time interval between the
last administration and sacrifice in the previous12,42 and the present studies was longer than 1 hour. The levels of
p-Akt were undetectable in the acute and short-term studies12,42, but were observed in this chronic study, which
suggests that chronic administration of antipsychotic drugs might be able to have prolonged effects on Akt activity and thereby on Akt-GSK3β signalling.
Although aripiprazole, bifeprunox and haloperidol were able to influence GSK3βactivity in the present study,
their effects on GSK3βwere not identical in each brain region. In the PFC, administration of aripiprazole and
bifeprunox, but not haloperidol, was able to suppress the activity of GSK3βvia the Akt-GSK3βsignalling pathway.
Aripiprazole and bifeprunox also decreased total protein levels of both Akt and GSK3βin response to the chronic
treatment of these two drugs. It has been suggested that inhibition of GSK3βcontributes to the therapeutic effects
of antipsychotics48 and the functional impairment in the PFC is related to the negative symptoms and cognitive
deficits of schizophrenia54. Our results suggested that the therapeutic effects of aripiprazole on the negative symptoms and cognitive deficits of schizophrenia might be attributed to its inhibiting effects on GSK3βactivity in the
PFC. Furthermore, bifeprunox was able to improve the negative symptoms of schizophrenia in clinical trials55
and it inhibited the activity of GSK3βin the present study, which further confirms that suppression of GSK3β
activity is very likely to be associated with the effects of antipsychotics on the negative and cognitive symptoms
Scientific Reports | 6:30040 | DOI: 10.1038/srep30040
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Figure 7. A proposed schematic diagram illustrating the chronic effects of aripiprazole and haloperidol on
cellular signalling in the nucleus accumbens. D2 receptor antagonists (e.g. haloperidol) and D2 receptor partial
agonists (e.g. aripiprazole) bind with the dopamine D2-like receptor, resulting in the phosphorylation of Akt
and the subsequent phosphorylation of GSK3βprobably via biasedly antagonising D2R-mediated β-arrestin2,
together with the activation of the Dvl-GSK3β-β-catenin pathway (A), which might contribute to the therapeutic
effect of antipsychotics. On the other hand, antagonism of the D2-like receptors by aripiprazole and haloperidol
leads to increased expression of GABAA (β-1) receptors probably via the activation of PKA activity (indicated as
a dashed arrow) (B), and enhanced CREB1 activity via the activation of GSK3βactivity and PKA activity
(C), both of which might also be involved in the therapeutic actions of antipsychotics.
of schizophrenia. In contrast, haloperidol did not display any significant effects on GSK3βin the PFC in the
present study and a previous acute study42, which may explain why haloperidol does not have therapeutic effects
on the negative symptoms and cognitive deficits of schizophrenia. It should be noted that the present study did
not found any changes of β-catenin, CREB1 and GABAA receptor in the PFC. Therefore, whether antipsychotics
control the negative symptoms and cognitive deficits of schizophrenia via the enhancement of Akt-GSK3β signalling requires further validations. In the NAc, administration of all three drugs increased the phosphorylation of
both Akt and GSK3βin the present study. Since abnormal function of the NAc is linked to the positive symptoms
of schizophrenia56, our results indicated that the suppression of GSK3βfunctions via the Akt-GSK3β signalling
pathway in the NAc is very likely to be involved in the therapeutic effects of antipsychotics (probably on the
positive symptoms of schizophrenia) (Fig. 7A). In the CPu, chronic treatment with these antipsychotics had very
limited effects on the Akt-GSK3βsignalling pathway, which suggests that GSK3βactivity in the CPu may not be
involved in the long-term clinical effects of antipsychotics. Yager et al.57 have reviewed that the NAc and CPu
are heterogeneous structures with different neural inputs and outputs connected with various brain regions. For
example, the NAc receives dopaminergic inputs from the ventral tegmental area, while sending outputs to limbic
areas and the PFC; the CPu receives dopaminergic inputs from the substantia nigra pars, while sending projections to neocortical areas57. Therefore, chronic antipsychotic treatment might have different in the NAc and CPu.
However, the brain-regional differences in the effects of antipsychotics require further clarification.
Previously, various classes of antipsychotics (e.g. aripiprazole, haloperidol, clozapine and risperidone) have
been found to be able to increase the expression of Dvl-3 and/or β-catenin in various brain regions of animals,
including the frontal cortex and striatum, indicating enhanced activity of β-catenin in these brain areas8–11. The
current data has demonstrated that Dvl-3 and β-catenin expression was significantly increased by administration
of both aripiprazole and haloperidol in the NAc only. These results are partly consistent with those of previous
studies. Since dysfunction of the NAc is associated with the positive symptoms of schizophrenia and the main
target of antipsychotics56 as mentioned above, the present study suggests that regulation of β-catenin via GSK3β
might be a common mechanism by which antipsychotics exert their effects, even if they have different pharmacological profiles (Fig. 7A). It is further suggested that the increased expression of β-catenin in the NAc is very likely
to be a route through which antipsychotics exert their therapeutic effects, especially on the positive symptoms of
schizophrenia.
It has been reported that chronic haloperidol administration increased the binding of GABAA receptors in the
NAc; and both haloperidol and clozapine administration also increased GABAA receptor binding in the limbic
cortex25. A recent short-term study has demonstrated that both aripiprazole and haloperidol increased GABAA
(containing β-1) receptor expression in the NAc (although the increasing effect of haloperidol did not reach
significance)17, which is validated by the present study. In this study, we found that chronic administration of
Scientific Reports | 6:30040 | DOI: 10.1038/srep30040
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aripiprazole and haloperidol were able to significantly increase GABAA (containing β-1) receptor expression in
the NAc, but no effects were shown in the other two brain regions. Since dysfunction of the NAc is related to the
positive symptoms of schizophrenia56 as mentioned above, our findings together with other studies, suggest that
increased GABAA receptor expression and probably enhanced GABAA signalling transmission in the NAc is very
likely to be involved in the therapeutic effects of antipsychotics (possibly on the positive symptoms of schizophrenia) (Fig. 7B). It is worth noting that the GABAA receptor is regulated by D2-like receptor downstream PKA signalling58,59. A 1-week study has revealed that PKA phosphorylation levels in the NAc, paralleling the expression
of GABAA receptors, was increased by aripiprazole and haloperidol17. In this chronic study, the effects of aripiprazole and haloperidol in increasing GABAA receptor expression persisted, whereas the changes in PKA activity
were undetectable. The reason is unknown. It is possible that the up-regulated expression of GABAA receptors by
short-term antipsychotic drug administration (through PKA) is an adaptive and prolonged change; even if there
was no further alteration in PKA activity after chronic administration (probably due to adaptive changes in D2Rs),
the increased GABAA receptor expression could be maintained.
A variety of studies has indicated dysfunction of NMDARs in schizophrenia5. In the current study, both aripiprazole and haloperidol administration was able to increase the expression of NMDAR subunits in the NAc, but
reduce it in the PFC. Specifically, aripiprazole increased the expression of both NR1 and NR2A in the NAc, while
haloperidol increased NR1 expression; in the PFC, both aripiprazole and haloperidol decreased NR2A levels.
Previously, Segnitz et al.41 have reported that NR2A mRNA levels were decreased in the PFC by aripiprazole
treatment for 4 months, but not changed in the CPu; Schmitt et al.40 have also found reduced NR2A mRNA in the
PFC induced by both haloperidol and clozapine treatment. Furthermore, it was found that 4-week administration
with haloperidol and D2-like receptor antagonist – raclopride increased the levels of both protein and mRNA
of NR1 in the striatum39. Additionally, [3H]-MK-801 binding in the NAc was increased by haloperidol40. These
previous findings are consistent with those of this study that both typical and atypical antipsychotics can increase
NMDARs expression in the striatum (particularly in the NAc, but not in CPu), and reduce NR2A expression in
the PFC. It is worth noting that antipsychotics have very low affinity with NMDARs. Therefore, it is necessary to
further reveal through which pathway(s) antipsychotics regulate NMDARs.
Previously, haloperidol was able to increase phosphorylation levels of CREB1 in the striatum and hippocampal neuron culture28–30. In addition, amisulpride, clozapine and olanzapine were also able to induce CREB1 phosphorylation in in vitro studies31–33. A 1-week in vivo study has shown that a 1-week administration of aripiprazole
increased the expression of CREB1 in the NAc17. In the present study, chronic administration of aripiprazole
increased CREB1 expression in the NAc; and both aripiprazole and haloperidol enhanced CREB1 activity via
increasing the ratio of p-CREB1/CREB1. This confirmed that CREB1 is involved in the actions of antipsychotics.
Moreover, extensive communication occurs between CREB1 and PKA, and the Akt-GSK3β pathway60. In the
present study, we did not observe any change in PKA activity, nor in the correlation between PKA and CREB1
activity in the NAc (indicated as a dashed arrow in Fig. 7C). However, GSK3βactivity is positively correlated with
CREB1 activity. A previous study has indicated that CREB1 activity was increased by inhibition of GSK3βin cultured rat cerebral cortical neurons33. Amisulpride also induced the phosphorylation of CREB1 via the Akt-GSK3β
pathway in SH-SY5Y cells32. Since patients with novel variants in the CREB1 gene experienced the positive symptoms of schizophrenia27, our data suggests that activation of CREB1 via the Akt-GSK3βpathway in the NAc is
very likely to be associated with the therapeutic effects of aripiprazole and haloperidol on the positive symptoms
of schizophrenia (Fig. 7C). It is worth noting that Mavrikaki et al.34 suggested that phosphorylation of CREB1 was
increased by 3-week injection of aripiprazole in the PFC and striatum of rats, probably through NMDA receptors. The regulation of CREB1 via NMDARs has also been confirmed by other studies61,62. The present study has
shown both aripiprazole and haloperidol were able to increase CREB1 phosphorylation and NMDAR expression
in the NAc, simultaneously. Whether the increased expression of NMDARs (partly) contributes to the enhanced
phosphorylation of CREB1 in the NAc requires further validations. Lastly, phosphorylation of histone H3S10, an
epigenetic modification, has been reported to be significantly increased in schizophrenia patients63. Since histone
H3 phosphorylation could be regulated by G protein-coupled receptor and NMDAR signalling64, it is important
to further investigate how the modulations of antipsychotics on these signalling pathways contribute to their
therapeutic effects.
In summary, the present study has demonstrated that chronic administration of aripiprazole had different effects on the Akt-GSK3β, Dvl-GSK3β-β-catenin, GABAA receptor and CREB1 activity in a brain
region-dependent manner. Compared to the effects of haloperidol only in the NAc and bifeprunox mainly in
the PFC, aripiprazole affected these cellular signalling pathways in both the PFC and NAc, which may explain its
unique clinical effects. It is also worth noting that the present and previous studies mentioned above examined
the effects of antipsychotic drugs in healthy animals. It is necessary to investigate the effects of antipsychotics in
the animal models for schizophrenia and other mental disorders in future studies.

Methods

Animals and drug administration.

Male Sprague-Dawley rats (aged 8 weeks) were obtained from the
Animal Resource Centre (Perth, Australia). After arrival, all rats were housed in individual cages under environmentally controlled conditions (temperature 22 °C, light cycle from 07:00AM to 07:00PM), with ad libitum
access to water and standard laboratory chow diet. All experimental procedures were approved by the Animal
Ethics Committee (Application #: AE11/02), University of Wollongong, and complied with the Australian Code
of Practice for the Care and Use of Animals for Scientific Purposes (2004). All efforts were made to minimise
animal distress and prevent suffering.
Before drug administration commenced, the rats were trained for self-administration of the sweet cookie
dough pellets for a week. Then the rats were randomly assigned into one of the following drug treatment groups
(n = 6/group): aripiprazole (0.75 mg/kg; Otsuka, Japan), bifeprunox (0.8 mg/kg; Otava, Ukraine), haloperidol
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(0.1 mg/kg; Sigma, Australia), or vehicle. Drug powder mixed with the cookie dough pellets was delivered orally
3 times per day at 07:00AM, 03:00PM and 11:00PM for 10 weeks. This drug administration method aims to
mirror the human scenario of oral administration and has been well-established in our laboratory17,65,66. These
dosages were transferred from the recommended dosages in humans based on body surface area, according to
the FDA guidelines for clinical trials67,68. A 0.75 mg/kg aripiprazole, 0.8 mg/kg bifeprunox and 0.1 mg/kg haloperidol dosage in rats is equivalent to ~7.5 mg, ~8 mg and ~1 mg in humans (60 kg body weight), respectively,
all of which are within the recommended clinical dosages55,69,70. Moreover, the dosages used in this study have
been shown to be physiologically and behaviourally effective in rodents, without inducing EPS side-effects71–74.
After 10-week administration, all animals were euthanised in a CO2-filled chamber. Brains were immediately
removed and frozen in liquid nitrogen. All animals were sacrificed between 09:00AM and 11:00AM to minimise
circadian-induced variation of protein expression.

Brain dissection. The discrete brain regions were collected using a brain microdissection puncture technique, which has been well-established17,42. Specifically, based on the brain atlas75, three sections through the forebrain (Bregma 3.30 to 4.20 mm) were dissected for the PFC; and three sections through the striatum (Bregma 1.00
to 2.20 mm) were dissected for the NAc and CPu, respectively. Dissected tissue was kept at −80 °C for future use.
Western blots. Frozen brain samples were homogenised in homogenising buffer (9.8 ml NP-40 cell lysis
buffer (Invitrogen, #FNN0021) mixed with 100 μl Protease Inhibitor Cocktail (Sigma-Aldrich, #P8340), 100 μl
β-Glycerophosphate (Sigma-Aldrich, #G9422) and 33.3 μl phenylmethylsulfonyl fluoride (Sigma-Aldrich,
#P7626)). Protein concentration of each sample was measured by the DC Protein Assay (Bio-Rad, #500-0111).
Each sample containing 10 μg of protein was denatured at 95 °C, and loaded into 4–20% CriterionTM TGXTM
Precast Gels (Bio-rad, #5671095). The gels were run vertically in CriterionTM Vertical Electrophoresis Cell
(Bio-rad, #1656001) until the proteins separated, followed by the electrophoretical transfer of the proteins
to a polyvinylidene difluoride membrane in CriterionTM Blotter (Bio-rad, #1704071). All membranes were
then blocked by 5% skim milk powder and incubated in primary antibodies. Amersham Hyperfilm ECL (GE
Healthcare, #28-9068-36) and Luminata Classico Western HRP substrate (Millipore, #WBLUC0500) were used
to visualise the immunoreactive bands. All Western blot experiments were performed in duplicate to ensure
consistency.
The antibodies used in the present study to examine PKA activity were anti-PKA-Cα(1:1000; Santa Cruz,
#SC-903) and anti-phosphor-PKA-C (Thr197) (1:1000; Cell Signalling, #5661). The antibodies used to examine the GSK3β-involved pathways were anti-Akt (1:2000; Cell Signalling, #4691), anti-phosphor-Akt (Thr308)
(1:1000; Cell Signalling, #13038), anti-GSK3β (1:2000; Cell Signalling, #5676), anti-phospho-GSK3β (Ser9)
(1:1000; Cell Signalling, #9322), anti-Dvl-3 (1:1000; Santa Cruz Biotechnology, #SC-8027), anti-β-catenin
(1:1000; Santa Cruz Biotechnology, #SC-7963). The antibodies used to detect subunits of GABAA receptors were:
anti-GABAA β-1 (1:1000; Abcam, #ab154822), anti-GABAA β-2 (1:1000; Abcam, #ab156000), and anti-GABAA
β-3 (1:1000; Abcam, #ab98968). The antibodies used to examine NMDAR were anti-NMDAR1 (1:2000, Abcam,
#ab109182) and anti-NMDAR2A (1:500, Abcam, #ab124913). In addition, anti-CREB1 (1:2000, Abcam,
#ab32515) and anti-phospho-CREB11 (1:2000, Abcam, #ab32096) were used to measure the activity of CREB1.
Mouse anti-actin primary polyclonal antibody (1:10000; Millipore, #MAB1501) was used to determine the actin
levels. The secondary antibodies were HRP-conjugated anti-rabbit IgG antibody (1:3000; Cell Signalling, #7074)
and HRP-conjugated anti-mouse IgG antibody (1:3000; Cell Signalling, #7076). Examples of full pictures of the
blots for each antibody are shown in the Supplementary file.
Statistics.

All data were analysed using SPSS Statistics V22.0 program. The immunoreactive signals
were quantified using Bio-Rad Quantity One software. The data of each targeted protein were then corrected based on their corresponding actin levels. Data normal distribution was tested using histograms and a
Kolmogorov-Smirnov Z test. For statistical evaluation, one-way analysis of variance (ANOVA) was performed
if the data was normally distributed. The post-hoc Dunnett t test was used to compare each drug treatment
group with the control group. The results were normalised by taking the value of the control group as 100%.
Pearson’s correlation test was used to analyse the relationships among the measurements. Statistical significance
was accepted when p ≤  0.05.
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